期刊
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
卷 65, 期 3, 页码 736-739出版社
TAYLOR & FRANCIS LTD
DOI: 10.1271/bbb.65.736
关键词
ovalbumin; ovokinin; anti-hypertensive peptide; peptide design; spontaneously hypertensive rat (SHR)
We obtained a potent anti-hypertensive peptide, RPFHPF, by replacing the amino acid residues of ovokinin(2-7) (RADHPF), an orally active anti-hypertensive peptide derived front ovalbumin. After intravenous administration in anesthetized Wistar rats, the designed peptide [Pro(2), Phe(3)]-ovokinin(2-7) had a long-lasting hypotensive activity at a dose of 10 mg/kg, while that of ovokinin(2-7) was only transient even at a dose of 100 mg/kg. After oral administration in conscious spontaneously hypertensive rats (SHRs), [Pro(2), Phe(3)]-ovokinin(2-7) significantly lowered the systolic blood pressure in a dose-dependent manner. It is noteworthy that the minimum effective dose of [Pro(2), Phe(3)]-ovokinin(2-7) was 0.3 mg/kg, about one-thirtieth of that of ovokinin(2-7). On the other hand, orally administered [Pro(2), Phe(3)]-ovokinin(2-7) did not show any significant hypotensive effect in normotensive Wistar-Kyoto rats (WKYs) even at a dose of 3 mg/kg. Taken together, [Pro(2), Phe(3)]-ovokinin(2-7) proved to be an ideal, potent anti-hypertensive peptide with little effect on normal blood pressure when given orally.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据